New Cancer-Killing Drug : Dosterlimab
Tags: Science and Technology
A trial of 18 colorectal cancer patients in the US found that the cancer is curable without chemotherapy or surgery. All the patients involved in the trial were given a drug called Dostarlimab. The drug was given to the patients every three weeks for six months.
Experts say this is perhaps the first time in the history of modern medical science that an experimental procedure has been successful against the most dreaded disease.
What is Dostarlimab?
It is an immunotherapy drug from GlaxoSmithKline.
It consists of molecules created by the laboratory.
It acts as a substitute antibody. It is sold under the brand name Gemperly.
It was approved for medical use in the United States and the European Union in 2021.
Its side effects include vomiting, joint pain, itching, rash, fever, etc.
Findings of the experiment
The trial showed that immunotherapy alone (without chemotherapy, radiotherapy or surgery) has been the basis of cancer treatment.
It can completely cure patients with a specific type of rectal cancer called 'mismatch repair deficit' cancer.
No cases of progression of disease or recurrence had been reported during the treatment.
Within nine weeks of starting treatment, 81% of patients had less symptoms and a faster physical response.
How does the drug work?
It is a type of monoclonal antibody that blocks proteins called checkpoints that are made by immune system cells, such as T cells and some cancer cells.
The test used checkpoints that allow T cells to kill cancer cells.
When these checkpoints are blocked, T cells are free to kill cancer cells more efficiently.
Examples of checkpoint proteins found on T cells or cancer cells include PD-1, PD-L1, CTLA-4 and B7-1.
Please Rate this article, so that we can improve the quality for you -